Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

22.54 -0.44 (-1.91%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Assembly Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

July 17, 2023

From Assembly Biosciences, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 14, 2023

Via Benzinga

Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023

June 21, 2023

From Assembly Biosciences, Inc.

Via GlobeNewswire

Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection ↗

July 21, 2022

Via Benzinga

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023

June 07, 2023

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

May 23, 2023

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

May 04, 2023

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update

April 18, 2023

From Assembly Biosciences, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 03, 2023

Via Benzinga

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

March 22, 2023

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

February 15, 2023

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs ↗

December 19, 2022

Assembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334).

Via Benzinga

Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334

December 19, 2022

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334

November 14, 2022

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation

November 08, 2022

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

November 04, 2022

From Assembly Biosciences, Inc.

Via GlobeNewswire

NVIDIA To $140? Plus This Analyst Cuts PT On Assembly Biosciences By 82% ↗

October 24, 2022

Truist Securities cut the price target on Assembly Biosciences, Inc. (NASDAQ: ASMB) from $11 to $2. Assembly Biosciences shares gained 2.6% to trade at $1.58 on Monday.

Via Benzinga

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

October 24, 2022

From Assembly Biosciences, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022 ↗

October 24, 2022

Upgrades

Via Benzinga

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor

October 05, 2022

Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board

From Assembly Biosciences, Inc.

Via GlobeNewswire

Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗

July 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

7 Penny Stocks That Could Triple in 2022 ↗

June 22, 2022

Penny stocks are affordable and some with credible business models in all likelihood have the potential to generate superior returns.

Via InvestorPlace

Assembly Bio Commences Early-Stage Study of Drug to Treat Hepatitis B Viral Infection ↗

June 06, 2022

Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced Initiation of Phase 1b clinical study of its drug candidate ABI-H3733 for Chronic Hepatitis B Virus Infection

Via Benzinga

The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine ↗

May 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company ↗

April 30, 2022

I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings...

Via Talk Markets

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 25, 2021

Gainers XTL Biopharmaceuticals (NASDAQ:XTLB

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 24, 2021

Gainers iSpecimen (NASDAQ:ISPC) shares in...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 06, 2021

Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021 ↗

September 13, 2021

Upgrades For Bank of America Corp (NYSE:

Via Benzinga

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself ↗

September 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.